The article you requested is
Dr Nierenberg Replies
J Clin Psychiatry 2011;72(7):1015-1016 [letter]
Copyright 2011 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $40
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
We appreciate Dr Teboul’s careful reading of the publication that arose from our roundtable conference. His comments about the magnitude of a difference between active treatments using the NICE guidelines are reasonable up until he critiques the meta-analysis of mirtazapine and SSRIs. Here, he focuses on the slight remission rate difference in favor of mirtazapine (NNT = 23) and claims that we were misleading readers by failing to interpret “minor differences as anything more than clinically negligible.”